ES3047659T3 - Rimegepant for cgrp related disorders - Google Patents
Rimegepant for cgrp related disordersInfo
- Publication number
- ES3047659T3 ES3047659T3 ES22182756T ES22182756T ES3047659T3 ES 3047659 T3 ES3047659 T3 ES 3047659T3 ES 22182756 T ES22182756 T ES 22182756T ES 22182756 T ES22182756 T ES 22182756T ES 3047659 T3 ES3047659 T3 ES 3047659T3
- Authority
- ES
- Spain
- Prior art keywords
- rimegepant
- dose
- placebo
- subjects
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647794P | 2018-03-25 | 2018-03-25 | |
| US201862664761P | 2018-04-30 | 2018-04-30 | |
| US201862774285P | 2018-12-02 | 2018-12-02 | |
| US201862777180P | 2018-12-09 | 2018-12-09 | |
| US201862777625P | 2018-12-10 | 2018-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3047659T3 true ES3047659T3 (en) | 2025-12-04 |
Family
ID=68060723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22182756T Active ES3047659T3 (en) | 2018-03-25 | 2019-03-25 | Rimegepant for cgrp related disorders |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20210000814A1 (enExample) |
| EP (3) | EP3773572A4 (enExample) |
| JP (3) | JP2021519288A (enExample) |
| KR (1) | KR20200135465A (enExample) |
| CN (1) | CN112153969A (enExample) |
| AU (1) | AU2019242604B2 (enExample) |
| BR (1) | BR112020019396A2 (enExample) |
| CA (1) | CA3094693A1 (enExample) |
| DK (1) | DK4088720T3 (enExample) |
| ES (1) | ES3047659T3 (enExample) |
| FI (1) | FI4088720T3 (enExample) |
| IL (1) | IL277272B1 (enExample) |
| MX (1) | MX2020009856A (enExample) |
| PH (1) | PH12020551425A1 (enExample) |
| PL (1) | PL4088720T3 (enExample) |
| PT (1) | PT4088720T (enExample) |
| SG (1) | SG11202009199YA (enExample) |
| SI (1) | SI4088720T1 (enExample) |
| WO (1) | WO2019191008A1 (enExample) |
| ZA (2) | ZA202006190B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4088720T3 (da) * | 2018-03-25 | 2025-09-29 | Pfizer Ireland Pharmaceuticals Unlimited Company | Rimegepant til cgrp-relaterede lidelser |
| KR20210116560A (ko) * | 2019-01-20 | 2021-09-27 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 편두통 돌발을 치료하기 위한 cgrp 길항제 |
| CN114980862A (zh) * | 2019-12-17 | 2022-08-30 | 拜尔哈文制药股份有限公司 | Cgrp抑制剂的鼻内药物组合物 |
| CA3172358A1 (en) * | 2020-02-27 | 2021-09-02 | Biohaven Pharmaceutical Holding Company Ltd. | Oral fast-dispersing dosage form of rimegepant |
| CN115697378A (zh) * | 2020-03-23 | 2023-02-03 | 拜尔哈文制药股份有限公司 | 用cgrp抑制剂治疗肺部损伤的方法 |
| JP2023533634A (ja) * | 2020-03-29 | 2023-08-04 | バイオヘイブン・ファーマシューティカル・アイルランド・デジグネイテッド・アクティビティ・カンパニー | 片頭痛の予防的治療 |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| LT4243797T (lt) | 2020-11-16 | 2026-06-10 | Orcosa Inc. | Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| CA3202137A1 (en) * | 2020-11-19 | 2022-05-27 | Pfizer Ireland Pharmaceuticals | Compositions for improved delivery of cgrp inhibitors |
| CN117999078A (zh) * | 2021-03-02 | 2024-05-07 | Cgrp诊断公司 | 偏头痛的发生的治疗和/或降低 |
| WO2022251752A2 (en) * | 2021-05-25 | 2022-12-01 | Biohaven Pharmaceutical Ireland Dac | Dual treatment of migraine |
| CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
| WO2023055758A1 (en) * | 2021-09-29 | 2023-04-06 | Pfizer Ireland Pharmaceuticals | Preventative treatment of migraine |
| CN114010608A (zh) * | 2021-11-23 | 2022-02-08 | 莱默(北京)药业科技有限公司 | 一种瑞美吉泮冻干口崩片及制备方法 |
| CN115154469A (zh) * | 2022-07-22 | 2022-10-11 | 中国科学院广州生物医药与健康研究院 | 瑞美吉泮或其药学上可接受的盐在制备预防或治疗肥胖的药物中的应用 |
| WO2024062504A1 (en) * | 2022-09-22 | 2024-03-28 | Quisitive Therapeutics | Pharmaceutical composition comprising ubrogepant and administration thereof |
| WO2024211881A1 (en) * | 2023-04-06 | 2024-10-10 | Navinta, Llc | Rimegepant suspension |
| WO2024220974A1 (en) * | 2023-04-21 | 2024-10-24 | Navinta, Llc | Rimegepant fast-dissolving films for oral administration |
| CN117414352A (zh) * | 2023-11-22 | 2024-01-19 | 湖北广济医药科技有限公司 | 一种瑞美吉泮口溶膜剂及其制备方法 |
| WO2025193980A2 (en) * | 2024-03-13 | 2025-09-18 | CNS Biosciences, Inc. | Method of treating neuropathic pain using an anti-cgrp inhibitor |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US7704583B2 (en) | 1998-08-14 | 2010-04-27 | R.P.Scherer Technologies, Inc. | Embossed blister pack |
| GB9817793D0 (en) | 1998-08-14 | 1998-10-14 | Scherer Corp R P | The formation of indicia in the base of a blister pack for transference to a body cast therein |
| GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| CA2615463A1 (en) * | 2005-07-29 | 2007-02-08 | Merck & Co., Inc. | Heterocyclic benzodiazepine cgrp receptor antagonists |
| US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
| RS56556B1 (sr) * | 2012-02-27 | 2018-02-28 | Bristol Myers Squibb Co | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so |
| US20130225336A1 (en) * | 2012-02-28 | 2013-08-29 | Edward R. Harvey | Method and apparatus for teaching the throwing of a curveball without injury |
| EP2815749A1 (en) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| US10117836B2 (en) * | 2014-02-05 | 2018-11-06 | Merck Sharp & Dohme Corp. | Tablet formulation for CGRP active compounds |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| DK4088720T3 (da) * | 2018-03-25 | 2025-09-29 | Pfizer Ireland Pharmaceuticals Unlimited Company | Rimegepant til cgrp-relaterede lidelser |
| KR20210116560A (ko) * | 2019-01-20 | 2021-09-27 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 편두통 돌발을 치료하기 위한 cgrp 길항제 |
-
2019
- 2019-03-25 DK DK22182756.1T patent/DK4088720T3/da active
- 2019-03-25 KR KR1020207030358A patent/KR20200135465A/ko not_active Ceased
- 2019-03-25 EP EP19776794.0A patent/EP3773572A4/en not_active Withdrawn
- 2019-03-25 WO PCT/US2019/023940 patent/WO2019191008A1/en not_active Ceased
- 2019-03-25 JP JP2020551496A patent/JP2021519288A/ja not_active Withdrawn
- 2019-03-25 ES ES22182756T patent/ES3047659T3/es active Active
- 2019-03-25 US US16/767,134 patent/US20210000814A1/en not_active Abandoned
- 2019-03-25 MX MX2020009856A patent/MX2020009856A/es unknown
- 2019-03-25 AU AU2019242604A patent/AU2019242604B2/en active Active
- 2019-03-25 IL IL277272A patent/IL277272B1/en unknown
- 2019-03-25 PL PL22182756.1T patent/PL4088720T3/pl unknown
- 2019-03-25 EP EP22182756.1A patent/EP4088720B1/en active Active
- 2019-03-25 CN CN201980034240.4A patent/CN112153969A/zh active Pending
- 2019-03-25 PT PT221827561T patent/PT4088720T/pt unknown
- 2019-03-25 FI FIEP22182756.1T patent/FI4088720T3/fi active
- 2019-03-25 BR BR112020019396-8A patent/BR112020019396A2/pt unknown
- 2019-03-25 EP EP25192368.6A patent/EP4631944A3/en active Pending
- 2019-03-25 SI SI201930982T patent/SI4088720T1/sl unknown
- 2019-03-25 SG SG11202009199YA patent/SG11202009199YA/en unknown
- 2019-03-25 CA CA3094693A patent/CA3094693A1/en active Pending
-
2020
- 2020-05-27 US US16/884,196 patent/US11083724B2/en active Active
- 2020-09-10 PH PH12020551425A patent/PH12020551425A1/en unknown
- 2020-10-06 ZA ZA2020/06190A patent/ZA202006190B/en unknown
-
2021
- 2021-08-08 US US17/396,717 patent/US20220168295A1/en not_active Abandoned
-
2022
- 2022-05-05 ZA ZA2022/04929A patent/ZA202204929B/en unknown
-
2023
- 2023-07-18 JP JP2023116385A patent/JP2023134690A/ja active Pending
-
2026
- 2026-04-20 JP JP2026069265A patent/JP2026123097A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4088720A1 (en) | 2022-11-16 |
| EP4631944A3 (en) | 2025-12-24 |
| KR20200135465A (ko) | 2020-12-02 |
| PL4088720T3 (pl) | 2025-12-15 |
| SI4088720T1 (sl) | 2026-01-30 |
| EP4631944A2 (en) | 2025-10-15 |
| EP3773572A1 (en) | 2021-02-17 |
| WO2019191008A1 (en) | 2019-10-03 |
| AU2019242604B2 (en) | 2025-01-02 |
| US20220168295A1 (en) | 2022-06-02 |
| FI4088720T3 (fi) | 2025-11-14 |
| EP3773572A4 (en) | 2022-01-05 |
| ZA202204929B (en) | 2024-10-30 |
| US20200383969A1 (en) | 2020-12-10 |
| MX2020009856A (es) | 2020-10-08 |
| US20210000814A1 (en) | 2021-01-07 |
| CN112153969A (zh) | 2020-12-29 |
| BR112020019396A2 (pt) | 2021-01-05 |
| US11083724B2 (en) | 2021-08-10 |
| JP2021519288A (ja) | 2021-08-10 |
| EP4088720B1 (en) | 2025-09-03 |
| ZA202006190B (en) | 2025-07-30 |
| IL277272B1 (en) | 2024-09-01 |
| JP2026123097A (ja) | 2026-07-29 |
| AU2019242604A1 (en) | 2020-10-22 |
| CA3094693A1 (en) | 2019-10-03 |
| DK4088720T3 (da) | 2025-09-29 |
| PH12020551425A1 (en) | 2021-12-13 |
| JP2023134690A (ja) | 2023-09-27 |
| SG11202009199YA (en) | 2020-10-29 |
| IL277272A (en) | 2020-10-29 |
| PT4088720T (pt) | 2025-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11083724B2 (en) | Rimegepant for CGRP related disorders | |
| US20210196699A1 (en) | Cgrp antagonists for treating migraine breakthrough | |
| BR112020014596A2 (pt) | Formulações, composições e métodos farmacêuticos de peptídeo yy | |
| ES2353690T3 (es) | Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger. | |
| JP2010529128A (ja) | レット症候群および他の障害の処置 | |
| US20060135422A1 (en) | Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE | |
| RU2744878C2 (ru) | Ингибиторы дипептидилпептидазы-4 для местного офтальмологического лечения нейродегенеративных заболеваний сетчатки | |
| CA3176432A1 (en) | Preventative treatment of migraine | |
| IL295926A (en) | Fast-dispersing oral dosage form of Rimgefent | |
| US20040248788A1 (en) | Hypertenson treatment | |
| US20170266111A1 (en) | Local administration-type pharmaceutical for improving dysphagia | |
| US20140107130A1 (en) | Oral Solution Formulations of Aripiprazole | |
| US20230285380A1 (en) | Dual treatment of migraine | |
| EA045801B1 (ru) | Фармацевтическая композиция римегепанта в форме быстродиспергирующейся пероральной лекарственной формы | |
| US20110195996A1 (en) | Transmucosal Treatment Methods in Patients With Mucositis | |
| TW202416979A (zh) | 用於治療急性壓力症之方法及組合物 | |
| WO2023055758A1 (en) | Preventative treatment of migraine |